Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 12;50(1):8-18.
doi: 10.64719/pb.4597.

Asenapine in the Treatment of Bipolar Depression

Rif S El-Mallakh  1 , Sharon Nuss  1 , Dong Gao  1 , Yonglin Gao  1 , Surriya Colleen Ahmad  1 , Clare Schrodt  1 , Caleb Adler  1
Affiliations

Asenapine in the Treatment of Bipolar Depression

Rif S El-Mallakh et al. Psychopharmacol Bull. .

Abstract

Objectives: Asenapine, a potent serotonin 7 (5-HT7) receptor antagonist, was examined for efficacy as an antidepressant in depressed bipolar subjects. It was predicted that subjects with the genetic variant of the short form of the serotonin transporter (5HTTR) would be more likely to respond.

Experimental design: A subset of patients participating in a randomized, placebo-controlled study of the efficacy of asenapine in bipolar I depression also underwent genetic testing for the 5HTTR. Montgomery Åsberg Depression Rating Scale (MADRS) score was ≥ 26 prior to randomization to asenapine or placebo for 8 weeks. Gene testing was performed before breaking the blind.

Principal observations: Nine patients completing the study also underwent gene testing. At study end, the average MADRS improvement was -19.80 ± SD 8.59 for the 4 people randomized to asenapine and -3.80 ± 9.01 for the 5 people receiving placebo (P = 0.021, t = 2.88). Anxiety, as measured by the Hamilton Anxiety Rating Scale (HAM-A), also improved in asenapine-treated patients (-15.40 ± 6.15 vs. -2.80 ± 7.95, P = 0.023, t = 2.803). Six participants had the short form of the 5HTTR, and it is believed they influenced the significant outcome in this small sample.

Conclusions: While this is a very small sample, asenapine appears to have a beneficial effect on both depression and anxiety in depressed bipolar I patients compared to treatment with placebo. Due to the large fraction of subjects with the short form, the hypothesis that the SF-5HTTR might increase asenapine response could not be adequately tested.

Keywords: anxiety; asenapine; bipolar depression; bipolar disorder; depression; serotonin transporter.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The Mean Change from Baseline in MADRS Total Scores Throughout the Study
Figure 2
Figure 2
The Mean Change from Baseline in HAM-A Total Scores Throughout the Study
See this image and copyright information in PMC

References

    1. Fourth. Washington, DC: American Psychiatric Association; 2000. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Text Revision.
    1. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530–537. - PubMed
    1. Altshuler LL, Kupka RW, Hellemann G, Frye MA, Sugar CA, McElroy SL, Nolen WA, Grunze H, Leverich GS, Keck PE, Zermeno M, Post RM, Suppes T. Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation bipolar treatment outcome network. Am J Psychiatry. 2010;167(6):708–715. doi: 10.1176/appi.ajp.2009.09010105. doi: - DOI - PubMed
    1. Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unutzer J. Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry. 2007;68(8):1237–1245. - PubMed
    1. Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18(3):143–157. - PubMed

LinkOut - more resources